STAT3 DECOY in Head and Neck Cancer

Clinical Trial ID NCT00696176

PubWeight™ 16.45^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00696176

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy.	Cancer Discov	2012	2.31
2	Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy.	Clin Dev Immunol	2011	1.41
3	Therapeutic modulators of STAT signalling for human diseases.	Nat Rev Drug Discov	2013	1.33
4	EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.	Curr Mol Pharmacol	2010	1.29
5	NF-kappaB and STAT3 signaling in glioma: targets for future therapies.	Expert Rev Neurother	2010	1.25
6	Emerging drugs to treat squamous cell carcinomas of the head and neck.	Expert Opin Emerg Drugs	2010	1.25
7	Targeting EGFR resistance networks in head and neck cancer.	Cell Signal	2009	1.07
8	Mechanisms of tumor resistance to EGFR-targeted therapies.	Expert Opin Ther Targets	2009	0.96
9	Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets.	Future Oncol	2012	0.93
10	Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.	PLoS One	2013	0.91
11	Emerging translational approaches to target STAT3 signalling and its impact on vascular disease.	Cardiovasc Res	2015	0.83
12	Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases.	Curr Opin Clin Nutr Metab Care	2016	0.81
13	Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance.	Cancers (Basel)	2014	0.77
14	Interface of signal transduction inhibition and immunotherapy in melanoma.	Cancer J	2010	0.77
15	Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma.	Oncotarget	2016	0.77